Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
Strasbourg, France, April 18, 2018, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, presents a poster with promising preclinical data on a novel viral vector (pseudocowpox, PCPV) at the AACR (American Association for Cancer Research) Annual Meeting 2018, Chicago, IL, USA, April 14 – 18.
PCPV was found to be the most promising therapeutic candidate amongst the poxviridae evaluated by Transgene:
* It displayed the strongest immunogenicity, and the best ability to reduce tumor size and increase survival in immunocompetent mice carrying fast-growing tumors.
* It induced a very strong cellular response and showed an attractive cytokine/chemokine profile.
* It also induced a strong local secretion of IFN-α and impressive changes in the tumor micro-environment, including decreased frequency of immunosuppressive cells in the tumor.
The abstract is available on the AACR 2018 website (#LB-287) and will be published in Cancer Research in June 2018.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer